Table 1 Patient characteristics.

From: Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

  

1q Copies

Measure

All (N = 213)

3 (N = 169)

> 3 (N = 44)

p-value

Gender, n (%)

Male

113 (53)

96 (57)

17 (39)

0.041

Female

100 (47)

73 (43)

27 (61)

 

Age at autoSCT (years)

Median (range)

62.5 (34.1–79.9)

61.8 (34.1–79.9)

64.3 (45.1–76.4)

0.12

Race, n (%)

White

143 (68)

110 (66)

33 (77)

0.27

Black

41 (20)

34 (20)

7 (16)

 

Hispanic

18 (9)

17 (10)

1 (2)

 

Asian

7 (3)

5 (3)

2 (5)

 

Unknown

4

3

1

 

Year of autoSCT, n (%)

2010–2014

59 (28)

44 (26)

15 (34)

0.34

2015–2018

154 (72)

125 (74)

29 (66)

 

R-ISS, n (%)

I

40 (23)

37 (26)

3 (8)

0.032

II

114 (65)

88 (63)

26 (72)

 

III

22 (13)

15 (11)

7 (19)

 

Unknown

37

29

8

 

R2-ISS, n (%)

II

39 (25)

36 (30)

3 (9)

0.024

III

88 (57)

68 (56)

20 (63)

 

IV

27 (18)

18 (15)

9 (28)

 

Unknown

59

47

12

 

ISS, n (%)

I

71 (38)

61 (41)

10 (26)

0.19

II

64 (34)

47 (31)

17 (44)

 

III

54 (29)

42 (28)

12 (31)

 

Unknown

24

19

5

 

Induction treatment, n (%)

KRD

44 (21)

34 (20)

10 (23)

0.87

VCD

27 (13)

23 (14)

4 (9)

 

VD

29 (14)

24 (14)

5 (12)

 

VRD

88 (42)

70 (42)

18 (42)

 

Other

23 (11)

17 (10)

6 (14)

 

Unknown

2

1

1

 

Conditioning regimen, n (%)

Bu/Mel based

42 (20)

34 (20)

8 (18)

0.60

Mel

165 (77)

129 (76)

36 (82)

 

Other

6 (3)

6 (4)

0

 

Response prior to autoSCT, n (%)

sCR/CR

38 (18)

27 (16)

11 (25)

0.46

nCR/VGPR

98 (46)

78 (46)

20 (45)

 

PR

62 (29)

52 (31)

10 (23)

 

SD

6 (3)

4 (2)

2 (5)

 

PD

9 (4)

8 (5)

1 (2)

 

MRD status prior to autoSCT, n (%)

Negative

82 (38)

64 (38)

18 (41)

0.89

Positive

126 (59)

101 (60)

25 (57)

 

Not done

5 (2)

4 (2)

1 (2)

 

Presence of other high-risk cytogenetics, n (%)

del17

31 (15)

21 (12)

10 (23)

0.17

t(4;14)

30 (14)

24 (14)

6 (14)

0.97

t(14;16)

13 (6)

9 (5)

4 (9)

0.31

Proportion of cells with 1q + (1 additional copy)

Number of patients

148

148

  

Median (range)

0.2 (0.0–1.0)

0.2 (0.0–1.0)

  

Proportion of cells with 1q + (2 additional copies)

Number of patients

17

 

17

 

Median (range)

0.2 (0.0–0.9)

 

0.2 (0.0–0.9)

 

Proportion of cells with 1q + (≥ 3 additional copies)

Number of patients

22

 

22

 

Median (range)

0.3 (0.0–0.9)

 

0.3 (0.0–0.9)

 

Any post-transplant maintenance

No

31 (15)

27 (16)

4 (9)

0.34

Yes

182 (85)

142 (84)

40 (91)

 

Maintenance therapy, n (%)

Len +/- Dex

105 (58)

84 (59)

21 (53)

0.58

Len + PI +/- Dex

29 (16)

20 (14)

9 (23)

 

Len/Elotuzumab

21 (12)

18 (13)

3 (8)

 

Single agent PI

23 (13)

17 (12)

6 (15)

 

Other

4 (2)

3 (2)

1 (3)

 
  1. autoSCT autologous hematopoietic stem cell transplant, Bu/Mel busulfan, melphalan, CR complete response, Dex dexamethasone, ISS International Staging System, KRD carfilzomib, lenalidomide, dexamethasone, Len lenalidomide Mel melphalan, MRD minimal residual disease, n number, NA not available, nCR near complete response, PD progressive disease, PI proteasome inhibitor, PR partial response, R-ISS Revised International Staging System, sCR stringent complete response, SD stable disease, VCD bortezomib, cyclophosphamide, dexamethasone, VD bortezomib, dexamethasone, VGPR very good partial response, VRD bortezomib, lenalidomide, dexamethasone.
Back to article page